Medpace Holdings, Inc. $MEDP is Capital Impact Advisors LLC’s 8th Largest Position

Capital Impact Advisors LLC grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 211.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 83,962 shares of the company’s stock after buying an additional 56,967 shares during the quarter. Medpace makes up 3.7% of Capital Impact Advisors LLC’s portfolio, making the stock its 8th biggest holding. Capital Impact Advisors LLC’s holdings in Medpace were worth $47,157,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. AQR Capital Management LLC increased its position in Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after buying an additional 324,293 shares in the last quarter. Wasatch Advisors LP increased its position in Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares in the last quarter. Geode Capital Management LLC increased its position in Medpace by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock worth $374,836,000 after buying an additional 24,625 shares in the last quarter. Invesco Ltd. increased its position in Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after buying an additional 85,517 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in Medpace by 19.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 375,033 shares of the company’s stock worth $210,637,000 after buying an additional 60,883 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on MEDP. Robert W. Baird reduced their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Barclays reduced their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and reduced their price target for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Weiss Ratings cut Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Finally, BMO Capital Markets cut their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Medpace presently has an average rating of “Hold” and an average price target of $467.08.

Medpace Trading Down 1.0%

NASDAQ:MEDP opened at $457.09 on Thursday. Medpace Holdings, Inc. has a 12-month low of $294.07 and a 12-month high of $628.92. The stock has a 50-day moving average price of $454.30 and a 200 day moving average price of $500.75. The stock has a market capitalization of $13.05 billion, a P/E ratio of 28.73, a P/E/G ratio of 2.34 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter last year, the business posted $3.67 earnings per share. The firm’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.